In patients with multiple sclerosis (MS), glucocorticoids (GCs) might not be sufficiently able to restrain the immune system, possibly due to decreased GC sensitivity. This may be, at least partially, genetically determined. Previously, we reported a more aggressive disease course in patients with the glucocorticoid receptor (GR) gene ER22/23EK polymorphism, which has been shown to decrease GC sensitivity.
relative resistance to GC, and for which the underlying molecular mechanism seems to become more clear (8) .
The 9␤ SNP in the GR gene, an adenine to guanine nucleotide substitution, is located in the GR␤ part of the GR. In vitro data show that the G allele of this polymorphism leads to a more stable GR␤ mRNA and increased receptor protein expression of the GR␤ isoform, which may contribute to a relative GC resistance.
Increased expression of the GR␤ protein isoform has been associated with GC resistance in other inflammatory diseases (9) . A higher frequency of the 9␤ SNP was found in patients with rheumatoid arthritis (10) .
Recently, haplotypes have been constructed consisting of the polymorphisms in the GR gene to identify the association between phenotypical changes and particular risk alleles. Different haplotypes have been associated with different GC sensitivity (11) .
In the present study, we investigated whether one of the haplotypes, including the 9␤ or ER22/23EK polymorphisms, plays a role in the disease course in MS. We tried to confirm our previous finding while considering the effect of four other polymorphisms, by inferring haplotypes, in a larger group of MS patients. We hypothesized that patients having haplotypes associated with a decreased GC sensitivity have a more aggressive disease course.
Patients and Methods

Patients and controls
Blood for DNA analysis had been collected from 646 unrelated Dutch Caucasian patients with MS or a clinically isolated syndrome suggestive for MS (clinically isolated syndrome) (12) , recruited from the MS center at the Vrije Universiteit Medical Center, Amsterdam. Patients were excluded from the genetic analysis when their ancestors were non-Caucasians. In a previous study (7) , we included 253 of these patients (cohort 1). For the present study, we recruited 393 new patients (cohort 2), and for the patients in cohort 1, a longer follow-up was now available. Patients' files were scrutinized to obtain data on disease characteristics. Patients were seen regularly for follow-up every 1 or 2 yr to evaluate disease progression. As a measure of disease progression, we used the time to reach an Expanded Disability Status Score (EDSS) of six, which indicates the need for a unilateral walking aid. All patients gave informed consent, and approval had been obtained of the Medical Ethical Committee of the Vrije Universiteit Medical Center, Amsterdam.
Healthy Caucasian blood donors (317) were included as a control group. They had all given written informed consent to use their blood and DNA for scientific research purposes.
Genotyping
DNA was extracted from leukocytes using standard techniques. DNA was genotyped by allelic discrimination using the TaqMan ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) and TaqMan Universal PCR master mix (Applied Biosystems, Branchburg, NJ). The polymorphisms 9␤ (rs6198), TthIIII (rs10052957), ER22/23EK (rs6189 and rs6190, respectively), N363S (rs6195), and the BcII (rs41423247) were determined according to previously described methods (13, 14) .
We used the genotype data for each of the five polymorphisms to infer six haplotypes, on the basis of Bayesian linkage disequilibrium analyses using a statistical method for haplotype reconstruction: the Phase Reconstruction Method version 2.1 (15) . The six haplotypes were responsible for more than 99% of the total haplotypes generated.
In 608 patients and 317 controls, all five polymorphisms were determined, and haplotypes were inferred. With the Phase Reconstruction Method of the missing genotypes, haplotypes were calculated, using the haplotype with the best likelihood. Of nine patients, haplotypes had a too insecure likelihood, therefore, they were excluded from the analyses.
Statistical analysis
Primary data were the genotype frequencies of the six haplotypes as observed in the whole patient group and healthy controls. We analyzed whether the distributions of genotypes deviated from Hardy-Weinberg equilibrium.
Pearson's 2 was used to analyze whether having zero, one, or two copies of the haplotype 1-6 was associated with disease susceptibility or MS subtypes. There were no homozygous controls or patients for the ER22/23EK/9␤/TthIIII haplotype (haplotype 6). There was one homozygous MS patient for the N363S haplotype (haplotype 5), therefore, both these haplotypes were analyzed as haplotype carrier (carrier one or two copies, noncarrier zero copies).
Regression analysis was used to investigate the influence of carrying one of the haplotypes on disease susceptibility, onset type (relapse onset vs. progressive onset), and age of onset. For the first two dependent variables, we corrected for age and gender, for the latter only for gender.
To investigate whether clinical disease progression was influenced by the haplotypes, Cox regression analysis, using the time to reach EDSS 6, was performed. We corrected for onset type and use of disease-modifying therapy (DMT). Hazard ratios (HRs) were computed as estimates of relative risks. Because our study population partly overlapped a previous study in which we found an effect of having the polymorphism ER22/ 23EK on the disease course (7) in cohort 1, we also analyzed the new (i.e. cohort 2) and the old (i.e. cohort 1) separately. The main purpose was to evaluate whether a possible finding in the whole group could be attributed to a strong effect in cohort 1 only.
Results
Patient characteristics are shown in Table 1 .
Genotype distribution of polymorphisms
The ER22/23EK, BcII, and the N363S are mutually exclusive. Genotype distributions in patients and controls did not deviate from Hardy-Weinberg equilibrium.
Haplotypes
Frequencies of the haplotypes are shown in Fig. 1 . In the controls these allele frequencies were comparable, as well with those in the cohort of van den Akker et al. (16) (Table 2).
As described before, ER22/23EK was always present in combination with TthIIII allele, but not vice versa. In addition, the polymorphism ER22/23EK was always present in combination with 9␤ G allele, but not vice versa (13) . In our population the 9␤ variant was always found in combination with TthIIII, but not vice versa.
Disease susceptibility
The haplotypes (Table 2) had the same frequencies in MS patients as in healthy controls.
Onset type and age of onset
The haplotypes showed the same frequencies in MS subtypes, and there was no effect of carrying one of the haplotypes with regard to age of onset, corrected for sex, and onset type (data not shown).
Clinical disease progression
Cox regression analysis resulted in an increased HR to reach EDSS 6 for carriers of haplotype 6 compared with noncarriers ͓2.2; 95% confidence interval (CI) 1.4 -3.5; P ϭ 0.001͔. When corrected for onset type, sex, and the use of DMT, the HR was 2.3 (95% CI 1.5-3.7; P Ͻ 0.001). Figure  2 shows the Kaplan-Meier survival curves for the two groups. When Cox regression analysis was done for the two different cohorts separately, a significantly increased HR for carriers compared with noncarriers, corrected for DMT and onset type, was found in both cohort 1 (HR 3.1; P ϭ 0.003; 95% CI 1.5-6.5) and cohort 2 (HR 2.0; P ϭ 0.03; 95% CI 1.1-3.6). For the other haplotypes, including the TthIIII/9␤ haplotype (haplotype 4), there was no significant effect on time to reach EDSS 6 (HR 1.1 corrected for age of onset, sex, and use of DMT; P ϭ 0.6; 95% CI 0.8 -1.5).
Discussion
The present study shows an association between haplotype 6 (TthIIII, 9␤, and ER22/23EK) of the GR and a more aggressive disease course in MS. This confirms our previous study in which we found an association between the ER22/23EK polymorphism and a more aggressive disease course. Because a longer follow-up was available, we reevaluated that cohort and confirmed our previous observation. When analyzing only the new cohort, the same conclusions could be drawn. This supports the validity of the observation. In addition, we considered the possible effect of the other polymorphisms by inferring haplotypes, and found no obvious impact.
Differences in effect on the disease course of the haplotypes 4 and the haplotype 6 may be due to differences in the molecular effects. The 9␤ allele has a suppressive effect in transcriptional repression, via the nuclear factor-B pathway (17) , a mechanism that is important for the immune system. Conversely, the ER22/23EK polymorphism, which decreases the trans-activating capacity of the GR via the GRE pathway (18) , seems to play a role in the regulation of the set point of the hypothalamic-pituitary-adrenal (HPA) axis. In MS, transactivation processes may play a more important role in disease than trans-repression processes.
One study shows indeed an association with the ER22/ 23EK polymorphism and a decreased GC sensitivity, as measured with dexamethasone suppression test (1 mg) in Dutch healthy elderly (19) , and this was not found for the 9␤ polymorphism (11) . This suggests that the decreased GC sensitivity does not seem to result from linkage disequilibrium with the 9␤ polymorphism or linkage with TthIIII. In line with this, we did not find an association between the haplotype 4 and disease course. A recent study found that healthy male carriers of the 9␤ variant had higher total cortisol responses after social stress, but also elevated levels of ACTH after dexamethasone suppression test (0.25 mg) were found, which suggests a relative GC insensitivity on the HPA axis level (17) . Differences can be explained by different doses of dexamethasone or different study populations.
There are several drawbacks in this kind of association studies (18) . However, in our study there was a clear a priori hypothesis based on previous studies. The polymorphisms in this study have been associated with altered GC sensitivity, and especially for the ER22/23EK polymorphism, there is strong evidence that this is a functional polymorphism. In addition, accurate phenotyping and homogeneity of the study population, and replication of the study results, ensure high quality of a study.
Although the effects of these polymorphisms probably are small, life-long exposure as well as the effects on networks as complicated as the HPA axis and the immune system make effects on the disease course conceivable. One of the hypotheses is that relatively GC insensitive immune cells may lead to a more aggressive disease course, due to reduced control of the immune and inflammatory reactions (2) . The imbalance between these two systems in MS may at least partially be inherited as can be concluded from the results of our study.
